Buy Resmed

Logo for stock RMD (Resmed)

Amount

£
GBP

Latest price

$250.98
(£1.00 = $1.354)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$36.801B

P/E ratio

28.18

EPS

$8.906

Beta

0.77

Dividend rate

$2.07

Dividend yield

0.82%

About

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

CEO

Mr. Michael J. (Mick) Farrell

Employees

9,980

Sector

Health

Company HQ

SAN DIEGO, United States of America

Website

News

Logo for news article #0 (ResMed: A Sleeping Giant Hiding In Plain Sight)

ResMed: A Sleeping Giant Hiding In Plain Sight

ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership, yet trades below its historical earnings multiples, offering compelling value. The company's sticky, essential products and expanding digital platform create a powerful, recession-resistant business model with strong secular tailwinds. We forecast 10% compound annual growth through 2030, with shares offering 13-21% upside based on reasonable valuation multiples and robust earnings growth.

Seeking Alpha

June 09, 2025

Logo for news article #1 (ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?)

ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research

June 04, 2025

Logo for news article #2 (Top 15 High-Growth Dividend Stocks For June 2025)

Top 15 High-Growth Dividend Stocks For June 2025

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, though still short of my 12% annualized target. The June 2025 Top 15 stocks offer a 1.34% average dividend yield with a 22.82% 5-year dividend growth rate and are 25% undervalued.

Seeking Alpha

June 02, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.